INTRODUCTION
Current methods for detecting chromosomal abnormalities, such as cytogenetic analysis, often require lengthy laboratory procedures and have high costs as well as causing a significant delay in providing a diagnosis. In addition, cytogenetic analysis is not always possible, particularly when the numbers of cells obtained from the prenatal diagnosis is limited or where cell culture fails. In these cases, the trisomy can usually be detected only using molecular genetic techniques such as polymerase chain reaction (PCR) or fluorescent in situ hybridization (FISH).
One such method used for detecting trisomies is fluorescent PCR using polymorphic small tandem repeats (STRs). Of the three classes of hypervariable repeats, STRs appear to be the most suitable for quantitative analysis, as dinucleotide repeats have complicated amplification patterns while variable numbers of tandem repeats (VNTRs) alleles often differ significantly in size, making interpretation difficult. The amplification of STRs by fluorescent PCR is so sensitive that it can potentially be applied to detecting fetal trisomies by amplifying isolated fetal DNA from maternal blood samples. STRs have also been used at the extreme sensitivities of the single cell for DNA fingerprinting (1) for forensic applications (2) .
The quantitative nature of this technique allows the amount of PCR product to be determined and thus the amount of each PCR product from each allele to be compared, which allows peak ratios of abundance of one allele to the other to be calculated. Although Mansfield reported the first description of this method in 1993 (3), there have been only a few reports applying this technique clinically to trisomy detection in prenatal diagnosis (4) (5) (6) (7) (8) (9) (10) . This has been due mainly to the relatively high numbers of cells required for reliable diagnosis, as difficulties are encountered when these methods are applied to amplifying low numbers of cells (11) , which has proved to be very time intensive and difficult to interpret. Interpretation difficulties occur, as diagnoses may have to be deduced from potential double doses, difficulties encountered caused by preferential amplification.
STRs can also be used to determine the origin of the extra chromosome and, if maternally derived, whether the extra chromosome is derived from meiosis I or meiosis II (12) .
Our aim was to determine whether fluorescent PCR could be of practical value in a prenatal diagnostic setting and to apply these methods for single-cell analysis as well as investigate whether the parental origin of the additional chromosome could be determined.
MATERIALS AND METHODS
During a 10-week period, 212 pregnant women underwent amniocentesis to rule out fetal chromosomal abnormalities either due to maternal age or from previously detected ultrasound abnormalities. Informed consents were obtained from all patients (I. Department of Obstetrics and Gynaecology, Semmelweis University Medical School, Budapest). Ten milliliters of amniotic fluid was removed and 9 ml was used for cytogenetic analysis, while 1 ml was stored for molecular genetic analysis. Samples from each patient underwent karyotyping and trisomy 21 (using D21S11, D21S1413), trisomy 18 (using D18S51), and trisomy 13 (using D13S631 and D13S258) diagnosis using STR markers.
Cells from the stored 1 ml of amniotic fluid were centrifuged at 15,000 rpm for 10 min. The supernatant was discarded and 100 ul of resin from the Ready Amp Genomic Purification Method (Promega, WI) was added to the pelleted cells. The subsequent extraction procedure was performed as per the manufacturer's protocol. Three microliters of this DNA solution was then used for each PCR reaction,
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PCR amplification was carried out in two assays. The first assay used primers for the D21S11 marker (13) , and the second assay used primers for the D21S1413 marker. Primer sequences are listed in Table  I . The D21S11 forward primer was labeled at the 5' end with FAM, and the D21S1413 forward primer was labeled with HEX fluorescent dye. PCRs were performed in a total volume of 25 ul containing 3 ul of DNA solution prepared with the Promega kit, Taq polymerase buffer (Perkin Elmer), 200 uM dNTPs, 10 pmol of each primer, 1.5 mM MgC12, and 0.6 U of AmpliTaq (Perkin Elmer). After denaturation at 95°C for 5 min, 30 cycles at 95°C for 45 sec, 58°C (D21S11) and 54°C (D21S1413) for 45 sec, and 72°C for 60 sec were performed in a Perkin Elmer 2400 thermal cycler. Final extension was for 10 min.
Trisomy 18 Detection in Prenatal Diagnosis
PCR amplification was carried out with primers for the D18S51 marker. Primer sequences are listed in Table I . The D18S51 forward primer was labeled at the 5' end with FAM. PCRs were performed in a total volume of 25 ul containing 3 ul of DNA solution prepared with the Promega kit, Taq polymerase buffer (Perkin Elmer), 200 uM dNTPs, 10 pmol of each primer, 1.5 mM MgCl 2 , and 0.6 U of AmpliTaq (Perkin Elmer). After denaturation at 95°C for 5 min, 30 cycles at 95°C for 45 sec, 60°C for 45 sec, and 72°C for 45 sec were performed in a Perkin Elmer 2400 thermal cycler. Final extension was for 10 min.
Trisomy 13 Detection in Prenatal Diagnosis
PCR amplification was carried out in two assays: the first with primers for the D13S631 marker and the second with primers for the D13S258 marker (Genomic Data Base; Utah Marker Development Group, 1995). The D13S631 forward primer was labeled at 
Determination of the Parental Origin of the Extra Chromosome in Trisomy 18 Diagnosis
Two trisomy 18 samples from the previous study were amplified using fluorescent PCR of the D18S51 tetranucleotide STR marker to determine the paternal derivation of the extra chromosome. DNA from fetal liver and maternal and paternal blood were extracted using a commercially available kit (Promega) as above. PCR was performed using the same protocol as in the study above.
Trisomy 21 Diagnosis in Single Cells Using Multiplex PCR
Thirty-five single dissociated cells from four known trisomy 21 fetal livers and 19 single dissociated cells from two known disomic fetal livers were analyzed using D21S11 and D21S167 STR markers. The primer sequences for both primers are listed in Table I . The D21S11 forward primer was labeled at the 5' end with FAM and the D21S167 forward primer was labeled with HEX fluorescent dye.
PCRs were performed in a total volume of 25 ul containing the single cell, 2.5 ml Taq polymerase buffer (Perkin Elmer), 200 uM dNTPs, primer (15 pmol D21S11, 4 pmol D21S167, and 3 pmol amelogenin), 1.5 mM MgCl 2 , and 0.6 U AmpliTaq (Perkin Elmer). After denaturation at 95°C for 5 min, 41 cycles at 94°C for 45 sec, 60°C for 45 sec, and 72°C for 45 sec were performed in a Perkin Elmer 2400 thermal cycler. Final extension was for 10 min.
Analysis of PCR Product
Two microliters of PCR product was mixed with 24 ul of formamide and 1 ul of Genescan-500 TAMRA size standard [Applied Biosystems (ABI)]. The mixture was denatured at 95°C for 3 min and placed on ice until analysis. Electrophoretic analysis was performed using POP4 gel (ABI) and the ABI 310 genetic analyzer. The amplification products were analyzed by Genescan Analysis 2.1 software (ABI), and the relative peak areas were calculated.
RESULTS
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Stored amniotic fluid samples were tested by fluorescent PCR of both D21S11 and D21S1413 STR markers for detection of trisomy 21. Of the 212 stored amniotic fluid samples tested, 4 showed the trisomy 21 karyotype. The D21S11 marker was amplified from all samples, and in all trisomic cases the results were consistent with the cytogenetics results. Two trisomy 21 samples showed a characteristic triallelic pattern, with three STR peaks of similar intensity corresponding to three different alleles, while the other two trisomy 21 samples showed a characteristic diallelic pattern, with a fluorescent intensity ratio of 2:1 indicating a double dose. Twenty-three samples showed a homozygous pattern for D21S11 (Table II) . These 23 homozygous and all trisomic samples were subsequently amplified using primers for the D21S1413 STR marker. Of the 23 homozygous samples for the D21S11 marker, 19 showed heterozygosity for the D21S1413 STR. In all four trisomic samples the results obtained using the D21S1413 marker were concordant with the D21S11 markers and confirmed trisomy 21.
Representative results of two trisomy 21 cases obtained by D21S11 marker are shown in Fig 1. Figure 2 illustrates a sample that was homozygous for the D21S11 but heterozygous for the D21S1413 marker.
Trisomy 18 Detection in Prenatal Diagnosis
Of the 212 samples, three showed trisomy 18 karyotype according to the cytogenetic results. These three pregnancies were terminated and fetal liver tissues stored for further investigations. The number of homozygous and heterozygous samples for the examined marker and relative peak areas of heterozygous samples are shown in Table IIIa . In all cases PCR results were consistent with cytogenetic results. Two trisomy 18 (Fig. 3, top) samples showed a characteristic triallelic pattern, with three STR peaks of similar intensity corresponding to three different alleles, while one trisomy 18 (Fig. 3, middle) sample showed a characteristic diallelic pattern with a fluorescent intensity ratio of 2:1 Figure 3 (bottom) shows normal heterozygous disomic samples with a dosage ratio of 1:1.
Although ratio ranges of normal heterozygous and diallelic trisomic samples did not overlap, diallelic trisomic samples should be further investigated using further markers on each chromosome to determine the quantitative amplification of different alleles and thus the trisomy. 
Trisomy 13 Detection in Prenatal Diagnosis
Cytogenetic results indicated two trisomy 13 samples from the 212 samples. One sample showed a characteristic triallelic pattern for both chromosome 13 specific STR markers (similar to Fig. 1, top) , while another sample showed a diallelic pattern with a dosage ratioof2:l (similar to Fig. 1, middle) for both D13S258 and D13S631.
The number of homozygous and heterozygous samples for the examined markers and relative peak areas of heterozygous disomic samples are shown in Table  IIIb . Of the 212 samples, only 2 were homozygous and therefore uninformative for both markers. The electrophoretogram in Fig. 3 demonstrates a sample heterozygous for both investigated STR markers. In all informative cases, PCR results were consistent with cytogenetic results.
Determination of the Parental Origin of the Extra Chromosome in Trisomy 18 Diagnosis
Of the 212 samples tested, three showed abnormal karyotype for chromosome 18 according to the cytogenetic results. Two samples showed a triallelic pattern, strongly suggesting that the origin of the extra chromosome is from meiosis I.
In family "S" (Fig. 4) , the fetus inherited two chromosome 18 markers (298 and 306) from the mother and a single chromosome 18 marker (286) from the father. The paternal chromosome 18 marker 302 was not inherited.
In family "V" (Fig. 5) , the fetus inherited two chromosome 18 markers (282 and 314) from the mother and a single chromosome 18 marker (290) from the father. The paternal chromosome 18 marker 302 was not inherited.
Therefore in both cases, the additional chromosome is probably derived from maternal meiosis I nondisjunction.
Trisomy 21 Diagnosis in Single Cells Using Multiplex PCR
Reliability was 100% (35/35) for either D21 marker (D21S11, D21S167) and 74% (26/35) for both D21 markers in trisomic single cells and 100% (19/19) for either D21 marker and 79% (15/19) for both D21 markers in single disomic cells. Trisomy was defined as either a triallelic signal or an aggregated ratio (amount of PCR product of the first allele divided by that of the second, where ratios greater than 4 or less than 0.25 were disregarded) of less than 0.7 or greater than 1.3; disomy was defined as an aggregated intensity ratio of between 0.7 and 1.3. Accurate trisomy status could be determined from all the known trisomic cells by either the characteristic triallelic STR peaks in either STR or the characteristic double-dose effect (2:1 ratio) in both STRs when results from three or more single cells were aggregated (Table IV) . In all trisomy and disomy samples, STR results confirmed known karyotype and there were no cases in which one STR indicated trisomy and the other disomy. Sex diagnosis was simultaneously obtained in 63% (22/35) single trisomic cells and 63% (12/19) disomic cells. Figure 6 demonstrates simultaneous sexing, trisomy detection, and trisomy confirmation of a single cell. The need for two or more chromosome 21 markers was demonstrated, as preferential amplification was observed in both STRs, which limits diagnostic confidence when a triallelic signal was not obtained.
DISCUSSION
Our experiments demonstrate that fluorescent PCR amplification of STRs can be used for the reliable detection of trisomies of chromosomes 21, 18, and 13. This technique permits the detection of trisomies 4 hr in urgent cases, allowing amniocentesis and possible termination to be undertaken the same day. This is especially important in prenatal diagnosis when the pregnancy is relatively advanced, as delay may lead to gestation exceeding the legal limit for termination. The DNA preparation from amniotic fluid takes only 50 min using the DNA purification method (Promega) instead of the long phenol/chloroform extraction procedure. The length of PCR is 2 hr and the detection However, the use of a single STR at the single-cell level is limited, due to preferential amplification where the signals do not show the characteristic triallelic signal and are, therefore, reliant on double-dose ratios as the range of trisomic ratios overlaps that of disomic ratios (Table IV) . Therefore, in these cases it is necessary to provide a second STR system which will confirm the trisomy by either a triallelic signal or an additional double-dose response. For example, the use of two STR markers on chromosome 21 enables a much more accurate diagnosis of trisomy 21 to be undertaken. Further investigations, which are in progress, will determine the confidence rate of a quantitative multiplex fluorescent PCR both using this method and using further STR markers. These results also demonstrate that fluorescent PCR amplification of a D18 STR can be used to determine the parental of additional chromosomes. Although in both these cases the additional chromosome was maternally derived, it does demonstrate the potential for this technique to provide a rapid answer regardless of whether the additional chromosome is maternally or paternally derived. Appropriate STR markers could be used to determine the parental origin of potentially any chromosome.
This method, fluorescent PCR amplification of STRs, provides four distinct advantages: (a) a rapid diagnosis of trisomy status can be made whether triallelic or double-dose signals are obtained; (b) the parental origin of the additional chromosome can be established; (c) a reliable diagnosis can be obtained from limited numbers of cells (11) ; and (d) the method is rapid, taking only 2-3 hr, allowing termination to be performed the same day if necessary.
Fluorescent PCR, which is approximately 1000 times more sensitive than conventional PCR (14) , provides this method with rapid (5-hr) results and additional advantages: easy interpretation; quantitative signals, resulting in much more accurate diagnoses from double-dose results; and the ability to multiplex primers using up to eight different markers (1,2), allowing multiple results to be obtained from low numbers of cells.
As this technique is rapid and has a high reliability and accuracy for trisomy 21 detection at the single-cell level, it has significant applications in conventional prenatal diagnosis and preimplantation diagnosis of genetic disease as well as potential for the diagnosis of trisomies from fetal cells in the maternal circulation.
